Ambio Pharm Inc. Reports Positive Phase I Results for SCAM-47, Advancing Multi-Pathway Peptide Research
New York, NY – April 28, 2026 – Ambio Pharm Inc. announced today that its investigational peptide SCAM-47 (Synthetic Colloidally Aggregating Motif-47) has successfully completed Phase I clinical evaluation, with…